Apogee Therapeutics Inc. $APGE Shares Sold by Polar Capital Holdings Plc

Polar Capital Holdings Plc cut its stake in Apogee Therapeutics Inc. (NASDAQ:APGE) by 3.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 503,539 shares of the company’s stock after selling 20,555 shares during the period. Polar Capital Holdings Plc’s holdings in Apogee Therapeutics were worth $38,007,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in Apogee Therapeutics by 2.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock worth $540,000 after acquiring an additional 152 shares in the last quarter. Stifel Financial Corp raised its stake in shares of Apogee Therapeutics by 3.5% in the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock valued at $394,000 after purchasing an additional 175 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its position in shares of Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after purchasing an additional 246 shares during the last quarter. Comerica Bank lifted its position in shares of Apogee Therapeutics by 1.0% during the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock worth $2,708,000 after purchasing an additional 338 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Apogee Therapeutics in the fourth quarter worth about $37,000. 79.04% of the stock is currently owned by institutional investors.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $83.38, for a total value of $1,667,600.00. Following the completion of the transaction, the chief executive officer owned 1,095,987 shares in the company, valued at approximately $91,383,396.06. This represents a 1.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total transaction of $432,905.00. Following the completion of the sale, the insider owned 205,648 shares in the company, valued at $16,186,554.08. The trade was a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 76,500 shares of company stock worth $6,323,295. Corporate insiders own 24.30% of the company’s stock.

Analyst Ratings Changes

APGE has been the subject of several research analyst reports. The Goldman Sachs Group set a $89.00 price objective on Apogee Therapeutics in a report on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Monday, April 20th. Royal Bank Of Canada boosted their price target on Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a report on Monday, June 8th. Citigroup upped their price target on Apogee Therapeutics from $95.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Truist Financial reduced their price objective on Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating on the stock in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $114.56.

Apogee Therapeutics Trading Down 1.1%

NASDAQ:APGE opened at $85.24 on Wednesday. The stock has a 50 day moving average of $84.52 and a 200-day moving average of $77.61. The firm has a market capitalization of $5.28 billion, a PE ratio of -19.69 and a beta of 0.62. Apogee Therapeutics Inc. has a 52 week low of $34.34 and a 52 week high of $95.32.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.01. As a group, analysts predict that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor ROR?t, a master regulator of T cell-driven inflammatory pathways. By modulating ROR?t activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral ROR?t inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.